Covered recipient · General Payments record
CINDY E OWEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$1,019.13
72 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,019.13 | 72 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $316.67 | 26 |
| Janssen Biotech, Inc. | $171.29 | 15 |
| Novartis Pharmaceuticals Corporation | $129.28 | 6 |
| Lilly USA, LLC | $125.23 | 13 |
| Regeneron Healthcare Solutions, Inc. | $109.08 | 4 |
| GENZYME CORPORATION | $98.95 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.18 | 2 |
| Amgen Inc. | $27.26 | 1 |
| LEO Pharma Inc. | $13.19 | 1 |
Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CINDY E OWEN
NPI 1598803819 · CMS profile ID 117868
Allopathic & Osteopathic Physicians / Dermatology
LOUISVILLE, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
72 matching records · $1,019.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 72.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.25 | 12/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887417031 | CMS |
| ABBVIE INC. | $6.48 | 12/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297873 | CMS |
| Lilly USA, LLC | $6.15 | 12/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917954257 | CMS |
| ABBVIE INC. | $16.58 | 11/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297871 | CMS |
| Lilly USA, LLC | $6.16 | 11/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917952635 | CMS |
| Janssen Biotech, Inc. | $1.85 | 11/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934677 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.23 | 11/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927310077 | CMS |
| ABBVIE INC. | $14.92 | 11/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297869 | CMS |
| Novartis Pharmaceuticals Corporation | $24.18 | 10/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894049523 | CMS |
| Lilly USA, LLC | $5.75 | 10/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917954411 | CMS |
| ABBVIE INC. | $5.22 | 10/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297867 | CMS |
| GENZYME CORPORATION | $22.62 | 10/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939002447 | CMS |
| ABBVIE INC. | $24.60 | 10/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297865 | CMS |
| Regeneron Healthcare Solutions, Inc. | $24.50 | 09/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927310073 | CMS |
| ABBVIE INC. | $4.91 | 09/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297863 | CMS |
| Lilly USA, LLC | $6.37 | 09/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917952287 | CMS |
| ABBVIE INC. | $11.13 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297861 | CMS |
| ABBVIE INC. | $14.84 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297859 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.93 | 08/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887417033 | CMS |
| ABBVIE INC. | $5.62 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297857 | CMS |
| GENZYME CORPORATION | $29.37 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939002421 | CMS |
| ABBVIE INC. | $14.74 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297855 | CMS |
| ABBVIE INC. | $16.68 | 08/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297853 | CMS |
| Janssen Biotech, Inc. | $1.33 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934703 | CMS |
| Janssen Biotech, Inc. | $23.08 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934709 | CMS |
| Lilly USA, LLC | $6.35 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917954255 | CMS |
| Lilly USA, LLC | $5.25 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917950217 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.25 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927310067 | CMS |
| ABBVIE INC. | $19.04 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297851 | CMS |
| GENZYME CORPORATION | $23.28 | 07/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939002403 | CMS |
| Janssen Biotech, Inc. | $16.15 | 07/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934687 | CMS |
| ABBVIE INC. | $10.87 | 07/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297849 | CMS |
| ABBVIE INC. | $5.24 | 07/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297847 | CMS |
| ABBVIE INC. | $5.19 | 07/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297845 | CMS |
| Lilly USA, LLC | $19.22 | 07/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917954991 | CMS |
| Janssen Biotech, Inc. | $4.23 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934681 | CMS |
| Janssen Biotech, Inc. | $16.54 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934693 | CMS |
| Janssen Biotech, Inc. | $20.16 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934699 | CMS |
| ABBVIE INC. | $4.91 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297843 | CMS |
| ABBVIE INC. | $5.68 | 05/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297841 | CMS |
| Lilly USA, LLC | $12.39 | 05/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917952633 | CMS |
| Janssen Biotech, Inc. | $18.09 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934715 | CMS |
| Novartis Pharmaceuticals Corporation | $21.13 | 05/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894049519 | CMS |
| ABBVIE INC. | $7.93 | 05/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297839 | CMS |
| ABBVIE INC. | $18.64 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297837 | CMS |
| ABBVIE INC. | $19.13 | 04/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891297835 | CMS |
| GENZYME CORPORATION | $23.68 | 04/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939002377 | CMS |
| Lilly USA, LLC | $5.26 | 04/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917954409 | CMS |
| Janssen Biotech, Inc. | $17.43 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934641 | CMS |
| Janssen Biotech, Inc. | $23.85 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885934647 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $848,779.58 | 205 |
| PY2024 | Principal investigator | $465,404.25 | 284 |
| PY2023 | Principal investigator | $512,761.61 | 145 |
| PY2022 | Recipient | $8.00 | 1 |
| PY2022 | Principal investigator | $318,333.10 | 76 |
| PY2021 | Recipient | $579.11 | 2 |
| PY2021 | Principal investigator | $303,603.63 | 109 |
| PY2020 | Recipient | $5,811.05 | 7 |
| PY2020 | Principal investigator | $509,738.55 | 72 |
| PY2019 | Recipient | $47,562.83 | 13 |
| PY2019 | Principal investigator | $1,244,974.63 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
77 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $3,358.00 | 12/26/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250671 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,957.00 | 12/26/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250673 |
| Principal investigator 1 | Eli Lilly and Company | $706.00 | 12/15/2022 | Non-covered Recipient Entity ARTHRITIS CONSULTANTS INC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 917823103 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $3,597.00 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433417 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $278.46 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433419 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $278.46 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433421 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $278.46 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433423 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $278.46 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433425 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $5,000.00 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433427 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,287.16 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433429 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,287.16 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433431 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,287.16 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433433 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,248.48 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433435 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,004.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433437 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,004.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433439 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,004.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433441 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,004.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433443 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,004.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433445 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,204.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433447 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,204.28 | 12/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937433449 |
| Principal investigator 1 | GENZYME CORPORATION | $4,460.72 | 12/12/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 935603429 |
| Principal investigator 1 | GENZYME CORPORATION | $3,590.00 | 12/05/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 935603421 |
| Principal investigator 1 | Bausch Health US, LLC | $500.00 | 12/02/2022 | Non-covered Recipient Entity DS RESEARCH | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 960342413 |
| Principal investigator 1 | Bausch Health US, LLC | $750.00 | 12/02/2022 | Non-covered Recipient Entity DS RESEARCH | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 960342415 |
| Principal investigator 1 | Bausch Health US, LLC | $10,025.12 | 12/02/2022 | Non-covered Recipient Entity DS RESEARCH | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 960342417 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,000.00 | 12/01/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 935609235 |
| Principal investigator 1 | Horizon Therapeutics plc | $8,490.00 | 11/28/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A PHASE 2A, OPEN LABEL, PROOF OF CONCEPT TRIAL OF DAXDILIMAB FOR THE TREATMENT OF MODERATE TO SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 937594353 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,470.00 | 11/28/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250665 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,277.00 | 11/22/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 935609257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 11/07/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250663 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 11/07/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 11/07/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250669 |
| Principal investigator 1 | Journey Medical Corporation | $500.00 | 11/04/2022 | Non-covered Recipient Entity Scott Health Services, LLC | DFD-29-CD-005 | No dispute reported | 06/30/2026 | 923103617 |
| Principal investigator 1 | GENZYME CORPORATION | $4,495.87 | 11/02/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 935603387 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,590.00 | 11/02/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 935603377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,108.00 | 10/27/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 885250661 |
| Principal investigator 1 | Journey Medical Corporation | $60,500.00 | 10/20/2022 | Non-covered Recipient Entity Scott Health Services, LLC | DFD-29-CD-005 | No dispute reported | 06/30/2026 | 923103601 |
| Principal investigator 1 | Journey Medical Corporation | $3,597.00 | 09/22/2022 | Non-covered Recipient Entity Scott Health Services, LLC | DFD-29-CD-005 | No dispute reported | 06/30/2026 | 923103897 |
| Principal investigator 1 | GENZYME CORPORATION | $3,947.00 | 08/08/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 935603314 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $211.02 | 07/22/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996519 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $148.38 | 07/22/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996521 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $207.45 | 07/22/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996523 |
| Principal investigator 1 | GENZYME CORPORATION | $1,500.00 | 07/18/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 935603323 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $148.38 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996525 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $211.02 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996527 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $217.62 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996529 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $207.45 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996531 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $97.20 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996533 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $18.30 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996535 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $148.38 | 07/15/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996537 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $490.00 | 07/12/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 935609031 |
| Recipient | Eli Lilly and Company | $8.00 | 07/11/2022 | Covered Recipient Physician | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 917806697 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $1,559.61 | 06/17/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996549 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $515.97 | 06/17/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996551 |
| Principal investigator 1 | Eli Lilly and Company | $3,819.00 | 06/14/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 917840093 |
| Principal investigator 1 | GENZYME CORPORATION | $9,500.00 | 06/13/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 935603331 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $1,732.90 | 06/13/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996553 |
| Principal investigator 1 | Journey Medical Corporation | $4,000.00 | 06/08/2022 | Non-covered Recipient Entity Scott Health Services, LLC | DFD-29-CD-005 | No dispute reported | 06/30/2026 | 923102273 |
| Principal investigator 1 | Eli Lilly and Company | $1,250.00 | 06/07/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 917840867 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,095.00 | 06/06/2022 | Non-covered Recipient Entity Dermatology Specialists Research-kentucky | Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 933191633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 05/16/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 2a Multi Center Randomized Double Blind Placebo Controlled Proof of Concept Study to Evaluate the Efficacy Safety and Tolerability of JNJ64304500 in Patients with Alopecia Areata | No dispute reported | 06/30/2026 | 885250659 |
| Principal investigator 1 | PFIZER INC. | $2,800.00 | 05/06/2022 | Non-covered Recipient Entity Scott Health Services LLC | A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 949744769 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $515.97 | 04/26/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996555 |
| Principal investigator 1 | Bausch Health US, LLC | $13,135.90 | 04/22/2022 | Non-covered Recipient Entity DS RESEARCH | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 960342411 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $4,209.66 | 04/14/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996557 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $500.00 | 04/05/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996559 |
| Principal investigator 1 | Eli Lilly and Company | $13,626.00 | 03/22/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 917841025 |
| Principal investigator 1 | Eli Lilly and Company | $523.00 | 03/08/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 917824861 |
| Principal investigator 1 | Eli Lilly and Company | $17,682.00 | 03/01/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | No dispute reported | 06/30/2026 | 917840855 |
| Principal investigator 1 | Eli Lilly and Company | $6,285.00 | 02/15/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 917840861 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,400.00 | 02/14/2022 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 935603287 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $3,500.00 | 02/10/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996561 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $1,000.00 | 02/10/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996563 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $500.00 | 02/10/2022 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949996565 |
| Principal investigator 1 | Eli Lilly and Company | $117.00 | 02/08/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 917824473 |
| Principal investigator 1 | Eli Lilly and Company | $14,103.00 | 02/08/2022 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 917841019 |
| Principal investigator 1 | Bausch Health US, LLC | $17,735.42 | 01/14/2022 | Non-covered Recipient Entity DS RESEARCH | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 960342409 |